Bausch Health plunges on adverse patent dispute decision
Shares of Canada-based Bausch Health Companies (TSX: BHC) tumbled more than 50% yesterday following an adverse US court ruling in a patent dispute over one of the company’s key drugs. The stock closed down 41% at $5.10.
Bausch Health and its gastroenterology business Salix Pharmaceuticals, today announced the US District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals et al v Norwich Pharmaceuticals regarding the infringement and validity of certain US patents protecting the composition and use of Xifaxan (rifaximin) 550mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.
The Oral Order indicates that the Court will find certain US patents protecting the use of Xifaxan for the reduction in risk of HE recurrence valid and infringed and US patents protecting the composition, and use of Xifaxan for treating IBS-D invalid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze